Analysis of Huntington's Disease Treatment market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
The global Huntington’s disease treatment market was estimated to have a market size worth US$ 360 Million in 2021 and is expected to grow at a CAGR of 20% from 2022-2032.
The market is estimated to reach US$ 2.7 Billion by the end of 2032.
The Huntington’s disease (HD) Treatment Market is expected to grow during the forecast period, reaching a global market size of US$ 432 Mn by the end of 2022.
Huntington’s disease affects approximately 31,000 people in North America, with a prevalence of 5.8 per 100,000 people. Ingrezza's expected label expansion to include chorea associated with Huntington's disease, together with the high incidence of Huntington’s disease in western countries, is anticipated to be major market drivers.
The prevalence of Huntington’s disease in children is much lower, with around 5.1% to 10% of all cases. The prevalence of HD in Europe is ten in 100,000
Market Size in 2021
US$ 360 Million
Market Size in 2022
US$ 432 Million
Forecasted Market Value in 2032
US$ 2.7 Billion
CAGR during the forecast period, 2022-2032
Market Share North America Expected During 2022
Key Players Offering Treatment for Huntington’s Disease
Don't Need a Global Report?
Save 40% on Country & Region specific reports
The global market for Huntington’s disease treatment expanded at a compound annual growth rate of 15.6% between 2015 and 2021, according to market research and competitive intelligence provider Fact.MR.
North-America was the dominant regional market during this time and held a significant share of global demand.
The market witnessed a slow growth rate of 7% from 2019 to the middle of 2020 due to the global COVID-19 pandemic. During the COVID-19 pandemic, online pharmacies were selling off-label drugs to manage symptoms associated with HD, such as antipsychotics, antidepressants, and anticonvulsants. Clinical trials were delayed during the COVID-19 pandemic due to the government-imposed blackout.
From 2022 and 2023, the market is forecast to grow at a y-o-y rate of 6.5%. According to most hospitals and clinics worldwide, the frequency of clinical visits for the diagnosis and treatment of HD has increased post the second quarter of 2021.
Because of this, the market will continue to grow with the expected growth rate beyond COVID-19. In the aftermath of the pandemic, clinical trials to develop a treatment for Huntington's disease have increased.
Growing Adoption of Improved Medical Treatments and Therapies to Drive Demand for Effective Treatments
Market growth is expected to be driven by the involvement of major market players in research for a cure for Huntington's disease (HD). There is a growing patient population and prevalence of diseases worldwide, mainly in North America and Europe. There will be further positive contribution to the market growth from the lack of disease-modifying drugs and other treatment methods available to HD patients.
As a potentially effective treatment for HD, stem cell therapy is generating interest. The ADORE-DH phase 2/ 3 trial uses CELLAVITA-HD, stem cell therapy being developed by Cellavita in collaboration with AzidusPharma. Additionally, alternative therapy options, such as speech therapy, psychological treatment, and physiotherapy, had a positive impact on the market growth for Huntington's disease treatment market.
Growing R&D Activities to accelerate the Market Growth
Research and development of Huntington's disease treatment methods continues to be made easier by the lack of a proper treatment or medication for the disease. This is expected to boost market growth significantly over the forecast period. Furthermore, government initiatives that encourage the development of new drugs are an important driver of the market's growth.
Global Huntington's disease treatment market is expected to grow due to increasing prevalence of disease and increased R&D activities by institutes and universities during the forecast period. The Huntington's disease Society of America estimates that there are approximately 30,000 symptomatic Americans and more than 200,000 people at risk for inheriting the disease.
Annexon Inc., for example, is developing ANX005-an experimental monoclonal antibody that addresses abnormal C1q activity in certain complement-mediated neurodegenerative diseases, such as Huntington's disease. In this innovative medication, C1q is suppressed along with the classical complement system, and it is administered intravenously (IV). The company started a phase 2 clinical trial of ANX005 in November 2020 to treat HD patients.
Failed therapies can be a significant threat to this market
The development of HD-specific therapies has been plagued by significant obstacles as several therapies have either failed to demonstrate efficacy or caused dangerous side effects. The Phase III trial GENERATION HD1 showed tominersen did not improve the symptoms of manifest HD, as F Hoffmann-La Roche Ltd discontinued the study in March 2021.
Data from phase III research has been analyzed by an unblinded Independent Data Monitoring Committee (iDMC) based on preliminary findings from that research. Upon analyzing these data, there was no indication of new or evolving safety signals for Tominersen.
The COVID-19 pandemic has had a slight negative impact on the market for Huntington's disease treatments. Clinical trials may be delayed due to the pandemic, which can delay the entry of pipeline candidates into the market.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Various measures towards preventing HD will drive this growth
In 2022, the North American market is expected to account for 77% of global revenue for Huntington's disease treatments. The increase in awareness and sales of Huntington's disease treatment products are a result of the high prevalence of Huntington's disease, the increased healthcare expenditure, technological advances, and proactive government initiatives.
Some of the major players in the market, including H. Lundbeck A/S and Teva Pharmaceutical Industries Ltd., have introduced symptom management products to support market growth.
Increasing product penetration will account for steady growth
Due to increasing product penetration, potential for growth, and growth in the prevalence of Huntington's disease in developing countries, the Asia Pacific market for Huntington's disease treatment is expected to grow rapidly over the forecast period with a projected 45% of the total revenue in this market.
As governments take more initiatives to improve the health status of the population, the market in the region is expected to grow.
Huntington's disease treatment is expected to dominate the market during the forecast period, with symptomatic treatment to account for 98% of market revenue in 2022.
The growth of this market is attributable to several symptom management products and their patent protection. First-line therapy for Huntington's chorea consists of xenazine and austedo. R&D of potential Huntington's disease product candidates may contribute to the growth of this segment.
In October 2021, SOM BIOTECH's drug SOM3355 was designated an orphan drug by the US Food and Drug Administration for the treatment of chorea associated with Huntington's disease.This is for use in the treatment of chorea associated with Huntington's disease. As a result, the product will be exclusively available in the U.S. after approval by the FDA.
Advanced therapies will drive this market
The disease-modifying therapies segment is expected to grow at the fastest rate over the forecast period. An increasing demand for advanced products, such as gene therapy and stem cell therapy, along with an increase in research and development for disease-modifying therapy are responsible for this growth.
The government's Fast Track Designation program by the US FDA could lead to accelerated registration processes, fueling the market in the years to come.
As an example, the US Food and Drug Administration granted fast track designation in September 2021 to Sage Therapeutics's candidate drug, SAGE-718, as a potential treatment for Huntington's disease. IQVIA predicts significant growth in US sales of tetrabenazine tablets 12.5 mg and 25 mg in the forecast period of 2022- 2032.
The disease-modifying therapies segment was valued at US$ 4.2 Bn in 2021 and is projected to reach US$ 9.83 Bn by 2032, growing at a CAGR of 9.1%.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Several key players are adopting various strategies to gain a larger share of the market, including new product development and partnerships.
- Premium Report Details -
- Let's Connect -
- Quick Contact -
- Get Started -
Get insights that lead to new growth opportunitiesBuy Now
Get A Special pricing for start-ups and universitiesEnquiry Before Buying
- Humble, Yet Honored -
As per Fact.MR, demand for Huntington’s disease treatment is forecast to register a CAGR of 20% from 2022 to 2032
By 2032, the Huntington’s disease treatment industry revenue is expected to be valued at US$ 2.4 Billion
Around 77% of all Huntingdon’s disease treatment is likely to be carried out across North America
As of 2022, the Huntington’s disease treatment landscape in the Asia Pacific is likely to yield a revenue share of 45%
Symptomatic treatment is likely to be the most preferred approach to Huntington’s disease, accumulating 98% revenue
By 2022-end, demand for Huntington’s disease treatment is forecast to reach US$ 432 Million
As of 2021, the Huntington’s disease treatment industry was valued at US$ 360 Million
From 2015-2021, the Huntington’s disease treatment market flourished at a CAGR of 15.6%,
Need An Exclusive Report For Your Unique Requirement?